TSVT
2seventy bio, Inc. [TSVT] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
TSVT Stock Summary
Top 10 Correlated Stocks
TSVT
In the News
TSVT Financial details
Company Rating
-
Market Cap
258.61M
Income
-213.02M
Revenue
100.39M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
274
Optionable
No
Shortable
Yes
Earnings
01 May 2024
P/E
-1.19
Forward P/E
-
PEG
0.3
P/S
1.44
P/B
0.69
P/C
-
P/FCF
-1.21
Quick Ratio
3.97
Current Ratio
4.08
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-4.32
EPS next Y
-
EPS next Q
-
EPS this Y
-38.01%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-20.46%
Revenue last 5Y
17.78%
Revenue Q/Q
-11.22%
EPS Q/Q
-20.71%
-
-
-
-
SMA20
0.4%
SMA50
-33.69%
SMA100
-47.7%
Inst Own
-
Inst Trans
-
ROA
-28%
ROE
-52%
ROC
-0.36%
Gross Margin
80%
Oper. Margin
-140%
Profit Margin
-123%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.535-12.69
52W High
-78.25%
52W Low
+161%
RSI
50.02
Rel Volume
0.21
Avg Volume
1.48M
Volume
308.58K
Perf Week
12.02%
Perf Month
-7.45%
Perf Quarter
-41.22%
Perf Half Y
-44.7%
-
-
-
-
Beta
1.851
-
-
Volatility
0.1%, 0.11%
Prev Close
-2.61%
Price
2.61
Change
-0.38%
Company Profile
- Volume Average 1.48M
- Market Capitalization 258.61M
- Employee 274
- CEO Mr. William D. Baird III, M.B.A.
- Headquarters Cambridge,MA,US
- IPO Date 2021-11-03
-
Website
https://www.2seventybio.com 
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
